Theravance Biopharma (TBPH) Tops Q3 EPS by 4c

Theravance Biopharma (NASDAQ: TBPH) reported Q3 EPS of ($0.17), $0.04 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $15.69 million versus the consensus estimate of $15.4 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Ardent Health revises 2025 non-GAAP figures after SEC staff talks
• JPMorgan Starts Bechtle AG (BC8:GR) (BECTY) at Neutral